Cargando…

Multivariable regression analysis of febrile neutropenia occurrence in early breast cancer patients receiving chemotherapy assessing patient-related, chemotherapy-related and genetic risk factors

BACKGROUND: Febrile neutropenia (FN) is common in breast cancer patients undergoing chemotherapy. Risk factors for FN have been reported, but risk models that include genetic variability have yet to be described. This study aimed to evaluate the predictive value of patient-related, chemotherapy-rela...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pfeil, Alena M, Vulsteke, Christof, Paridaens, Robert, Dieudonné, Anne-Sophie, Pettengell, Ruth, Hatse, Sigrid, Neven, Patrick, Lambrechts, Diether, Szucs, Thomas D, Schwenkglenks, Matthias, Wildiers, Hans
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3994907/ https://www.ncbi.nlm.nih.gov/pubmed/24641830 http://dx.doi.org/10.1186/1471-2407-14-201

Ejemplares similares

Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study
por: Pettengell, Ruth, et al.
Publicado: (2008)

Impact of baseline telomere length on survival and chemotherapy related toxicity in breast cancer patients receiving (neo)adjuvant anthracycline containing chemotherapy
por: Hatse, Sigrid, et al.
Publicado: (2022)

Hodgkin lymphoma treatment with ABVD in the US and the EU: neutropenia occurrence and impaired chemotherapy delivery
por: Schwenkglenks, Matthias, et al.
Publicado: (2010)

Incidence of neutropenia, chemotherapy delivery, and use of colony-stimulating factor in patients with non-Hodgkin lymphoma of different age groups
por: Pettengell, Ruth, et al.
Publicado: (2011)

Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphoma
por: Pettengell, Ruth, et al.
Publicado: (2011)

Erratum to: Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphoma
por: Pettengell, Ruth, et al.
Publicado: (2012)

Immune profiles of elderly breast cancer patients are altered by chemotherapy and relate to clinical frailty
por: Bailur, Jithendra Kini, et al.
Publicado: (2017)

Management of chemotherapy-associated febrile neutropenia
por: Cameron, D
Publicado: (2009)

Risk Factors for Febrile Neutropenia during Chemotherapy for HIV-Related Lymphoma
por: Park, Jinyong, et al.
Publicado: (2012)

Chemotherapy-induced neutropenia and febrile neutropenia in patients with gynecologic malignancy
por: Hashiguchi, Yasunori, et al.
Publicado: (2015)

Age-related microRNAs in older breast cancer patients: biomarker potential and evolution during adjuvant chemotherapy
por: Dalmasso, Bruna, et al.
Publicado: (2018)

Differences in the Tumor Molecular and Microenvironmental Landscape between Early (Non-Metastatic) and De Novo Metastatic Primary Luminal Breast Tumors
por: Lambrechts, Yentl, et al.
Publicado: (2023)

Association of reduced relative dose intensity and survival in lymphoma patients receiving CHOP-21 chemotherapy
por: Pettengell, R., et al.
Publicado: (2008)

Economic costs of chemotherapy-induced febrile neutropenia among patients with non-Hodgkin’s lymphoma in European and Australian clinical practice
por: Weycker, Derek, et al.
Publicado: (2012)

Chemotherapy-Induced Neutropenia and Febrile Neutropenia in the US: A Beast of Burden That Needs to Be Tamed?
por: Boccia, Ralph, et al.
Publicado: (2022)

Update on Febrile Neutropenia in Pediatric Oncological Patients Undergoing Chemotherapy
por: Cennamo, Federica, et al.
Publicado: (2021)

Bloodstream infection in pediatric patients with febrile neutropenia induced by chemotherapy
por: Lima, Mariana Antunes Faria, et al.
Publicado: (2023)

Evaluation of Febrile Neutropenia in Hospitalized Patients with Neoplasia Undergoing Chemotherapy
por: Bachlitzanaki, Maria, et al.
Publicado: (2023)

Dynamic alterations of immunosenescence-related genes in older women with breast cancer receiving chemotherapy: A prospective study
por: Wu, Qi, et al.
Publicado: (2022)

Baseline and early lymphopenia predict for the risk of febrile neutropenia after chemotherapy
por: Ray-Coquard, I, et al.
Publicado: (2003)

Granulocyte colony-stimulating factor (filgrastim) in chemotherapy-induced febrile neutropenia
por: Advani, S. H., et al.
Publicado: (2010)

Microbial Translocation Contribute to Febrile Episodes in Adults with Chemotherapy-Induced Neutropenia
por: Wong, Michelle, et al.
Publicado: (2013)

Febrile neutropenia in chemotherapy treated small-cell lung cancer patients
por: Kukec, Renata Rezonja, et al.
Publicado: (2015)

Macrophage Colony‐stimulating Factor Prevents Febrile Neutropenia Induced by Chemotherapy
por: Hidaka, Takao, et al.
Publicado: (2001)

Chemotherapy induced neutropenia and febrile neutropenia among breast cancer patients in a tertiary hospital in Nigeria
por: Salako, Omolola, et al.
Publicado: (2021)

Home administration of filgrastim (Nivestim™) in primary prophylaxis of chemotherapy-induced febrile neutropenia
por: Otremba, Burkhard, et al.
Publicado: (2018)

Incidence of febrile neutropenia with commonly used chemotherapy regimen in localized breast cancer
por: Palukuri, Nageswara Reddy, et al.
Publicado: (2020)

Pharmacokinetics and Pharmacodynamics of Cefepime in Adults with Hematological Malignancies and Febrile Neutropenia after Chemotherapy
por: Álvarez, José C., et al.
Publicado: (2021)

Validation of the FENCE Risk Groups for Prediction of Febrile Neutropenia With First-Cycle Chemotherapy
por: Zatarah, Razan, et al.
Publicado: (2022)

Predictors of Septic Shock or Bacteremia in Children Experiencing Febrile Neutropenia Post-Chemotherapy
por: Avilés-Robles, Martha, et al.
Publicado: (2022)

POLRMT as a Novel Susceptibility Gene for Cardiotoxicity in Epirubicin Treatment of Breast Cancer Patients
por: Velasco-Ruiz, Alejandro, et al.
Publicado: (2021)

Incidence and Impact of Baseline Electrolyte Abnormalities in Patients Admitted with Chemotherapy Induced Febrile Neutropenia
por: Shaikh, Asim Jamal, et al.
Publicado: (2011)

Technical evaluation of methods for identifying chemotherapy-induced febrile neutropenia in healthcare claims databases
por: Weycker, Derek, et al.
Publicado: (2013)

Pharmacokinetics of piperacillin/tazobactam in cancer patients with hematological malignancies and febrile neutropenia after chemotherapy
por: Álvarez, José C, et al.
Publicado: (2013)

Pegfilgrastim for primary prophylaxis of febrile neutropenia in breast cancer patients undergoing TAC chemotherapy
por: Lee, Jihyoun, et al.
Publicado: (2018)

The impact of the oral cavity in febrile neutropenia and infectious complications in patients treated with myelosuppressive chemotherapy
por: Zecha, Judith A. E. M., et al.
Publicado: (2019)

History and Outcome of Febrile Neutropenia Outside the Oncology Setting: A Retrospective Study of 76 Cases Related to Non-Chemotherapy Drugs
por: Andrès, Emmanuel, et al.
Publicado: (2017)

The reliability of FEbrile Neutropenia after ChEmotherapy (FENCE) scores in predicting granulocyte colony-stimulating factor breakthrough febrile neutropenia among patients with lymphoma undergoing first-cycle chemotherapy: A prospective observational study
por: Thungthong, Pravinwan, et al.
Publicado: (2023)

The use of chemotherapy regimens carrying a moderate or high risk of febrile neutropenia and the corresponding management of febrile neutropenia: an expert survey in breast cancer and non-Hodgkin's lymphoma
por: Gerlier, Laetitia, et al.
Publicado: (2010)

Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now?
por: Aapro, Matti, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_upnvdm1dk1ihev0lmhs6g0j2ce